# Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

> **NCT03644550** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** LMB-100
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03644550
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-04
- **Primary completion:** 2020-08-05
- **Final completion:** 2020-11-02
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first line treatment for Mesothelioma, the principal investigator decided to end the study early (prior to reaching enrollment goal).
- **Last updated:** 2021-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644550, "Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03644550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*